Morphoproteomics and bortezomib/dexamethasone-induced response in relapsed acute lymphoblastic leukemia.
"Morphoproteomics" is defined as the identification by immunohistochemistry of the molecular circuitry of various proteins in a tumor by noting their state of activation (translocation and phosphorylation) and correlative expressions. This approach can uncover potential targets, amenable to therapeutic interventions, that are specific for an individual patient's tumor (ie, customized chemotherapy). This communication illustrates the successful application of such an approach in a patient with relapsed acute lymphoblastic leukemia.
Brown
Robert E
RE
Division of Laboratory Medicine, Geisinger Medical Center, Danville, Pennsylvania 17822-0131, USA. rebrown@geisinger.edu
Bostrom
Bruce
B
Zhang
Ping L
PL
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000737:chemistry / Q000276:immunology; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D002648:Child; D003907:Dexamethasone / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D016328:NF-kappa B / Q000032:analysis / Q000378:metabolism; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis / Q000188:drug therapy*; D017346:Protein Serine-Threonine Kinases / Q000032:analysis / Q000378:metabolism; D040901:Proteomics; D011518:Proto-Oncogene Proteins / Q000032:analysis / Q000378:metabolism; D051057:Proto-Oncogene Proteins c-akt; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000032:analysis / Q000378:metabolism; D011719:Pyrazines / Q000627:therapeutic use*; D012008:Recurrence
D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D001897:Boronic Acids; D016328:NF-kappa B; D011518:Proto-Oncogene Proteins; D019253:Proto-Oncogene Proteins c-bcl-2; D011719:Pyrazines; D000069286:Bortezomib; D003907:Dexamethasone; D017346:Protein Serine-Threonine Kinases; D051057:Proto-Oncogene Proteins c-akt